Oberweis, C. V., Marchal, J. A., López-Ruiz, E. & Gálvez-Martín, P. A worldwide overview of regulatory frameworks for tissue-based products. Tissue Eng. B 26, 181–196 (2020).

Article  Google Scholar 

Jacques, E. & Suuronen, E. J. The progression of regenerative medicine and its impact on therapy translation. Clin. Transl. Sci. 13, 440–450 (2020).

Article  Google Scholar 

Goula, A. et al. Advanced therapy medicinal products challenges and perspectives in regenerative medicine. J. Clin. Med. Res. 12, 780–786 (2020).

Article  Google Scholar 

Sipp, D. & Okano, H. Japan strengthens regenerative medicine oversight. Cell Stem Cell 22, 153–156 (2018).

Article  Google Scholar 

Kim, D.-S. & Bae, S. Impact and challenges of enactment for advanced regenerative medicine in South Korea. Front. Bioeng. Biotechnol. 10, 972865 (2022).

Article  Google Scholar 

Qiu, T., Hanna, E., Dabbous, M., Borislav, B. & Toumi, M. Regenerative medicine regulatory policies: a systematic review and international comparison. Health Policy 124, 701–713 (2020).

Article  Google Scholar 

Hogle, L. F. & Das, A. The social production of evidence: regenerative medicine and the 21st Century Cures Act. Regen. Med. 12, 581–586 (2017).

Article  Google Scholar 

Brown, D. G. & Wobst, H. J. A decade of FDA-approved drugs (2010–2019): trends and future directions. J. Med. Chem. 64, 2312–2338 (2021).

Article  Google Scholar 

Butler, D. Translational research: crossing the valley of death. Nature 453, 840–842 (2008).

Article  Google Scholar 

Frederickson, R. M. Escaping the valley of death. Mol. Ther. 20, 476–478 (2012).

Article  Google Scholar 

Hinsenkamp, A., Benyó, Z. & Hornyák, I. Overview of tissue engineering patent strategies and patents from 2010 to 2020, including outcomes. Tissue Eng. B 28, 626–632 (2022).

Article  Google Scholar 

Allen-Hoffmann, L., Comer, A., Conrad, P. B., Hoffmann, M. & Ivarie, C. A.-R. Improved skin substitutes and uses thereof. Australian patent application 214639 B2 (2010).

Asano, S., Nakanishi, Y. & Sugiyama, D. Intellectual property in the field of regenerative medicine in Japan. Clin. Ther. 40, 1823–1827 (2018).

Article  Google Scholar 

Pirnstill, J. & Allen-Hoffmann, B. L. Cold storage of organotypically cultured skin equivalents for clinical applications. US patent 10743533 B2 (2022).

Allen-Hoffmann, B. L., Pirnstill, J. C., Gratz, K. R. & Comer, A. R. Cryopreservation of viable human skin substitutes. Australian patent 232795 B2 (2019).

Koepsel, J. & Gratz, K. Tissue container systems. US patent application 0330542 A1 (2022).

Smiell, J., Comer, A., Lokuta, M. & Allen-Hoffmann, B. L. Methods for treating acute wounds and improving outcomes. Australian patent application 353695 A1 (2020).

Wang, S.-J. Patent portfolios for biotech inventions. Nat. Biotechnol. 31, 501–503 (2013).

Article  Google Scholar 

Rachinsky, T. First-to-invent versus first-to-file: impact of the AIA. Pharm. Pat. Anal. 3, 353–359 (2014).

Article  Google Scholar 

Begley, C. G. & Ioannidis, J. P. A. Reproducibility in science. Circ. Res. 116, 116–126 (2015).

Article  Google Scholar 

Ozyhar, T., Barnabei, L. & Myrick, D. When speed matters: a discussion on the benefits of a grace period in patent law to accelerate pharmaceutical innovation in times of pandemic. J. Law Biosci. 9, lsac004 (2022).

Article  Google Scholar 

Sherkow, J. S. Preprint servers and patent prior art. EMBO Rep. 23, e54439 (2022).

Article  Google Scholar 

Armstrong, J. P. K. et al. A blueprint for translational regenerative medicine. Sci. Transl. Med. 12, eaaz2253 (2020).

Article  Google Scholar 

Crama, P., Reyck, B. D. & Degraeve, Z. Milestone payments or royalties? Contract design for R&D licensing. Oper. Res. 56, 1539–1552 (2008).

Article  MathSciNet  MATH  Google Scholar 

Nordberg, R. C., Otarola, G. A., Wang, D., Hu, J. C. & Athanasiou, K. A. Navigating regulatory pathways for translation of biologic cartilage repair products. Sci. Transl. Med. 14, eabp8163 (2022).

Article  Google Scholar 

Zscharnack, M. et al. Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP). J. Transl. Med. 13, 160 (2015).

Article  Google Scholar 

Cox, E. M., Edmund, A. V., Kratz, E., Lockwood, S. H. & Shankar, A. Regulatory affairs 101: introduction to expedited regulatory pathways. Clin. Transl. Sci. 13, 451–461 (2020).

Article  Google Scholar 

Kulkarni, T. N. & Kulkarni, N. G. Authoring a periodic adverse drug experience report…here’s what you need to know! Perspect. Clin. Res. 10, 95–99 (2019).

Article  Google Scholar 

Alapati, D., Egan, P. & Holcombe, J. Understanding conflict of interest for academic entrepreneurs. In Academic Entrepreneurship for Medical and Health Scientists. PubPub Edition (2021).

Collins, L. R. & Shepard, K. A. CIRM tools and technologies: breaking bottlenecks to the development of stem cell therapies. Stem Cell Transl. Med. 9, 1129–1136 (2020).

Article  Google Scholar 

Yuh, D. D. Value analysis committees: not just another committee to get out of. J. Thorac. Cardiovasc. Surg. 155, 686–687 (2018).

Article  Google Scholar 

Dang, A. & Kaur, K. Comparative effectiveness research and its utility in in-clinic practice. Perspect. Clin. Res. 7, 9–14 (2016).

Article  Google Scholar 

Westrich, K. D., Wilhelm, J. A. & Schur, C. L. Comparative effectiveness research in the USA: when will there be an impact on healthcare decision-making? J. Comp. Eff. Res. 5, 207–216 (2016).

Article  Google Scholar 

Carter, R. G. et al. Innovation, entrepreneurship, promotion, and tenure. Science 373, 1312–1314 (2021).

Article  Google Scholar 

Caulfield, T., Harmon, S. H. & Joly, Y. Open science versus commercialization: a modern research conflict? Genome Med. 4, 17 (2012).

Article  Google Scholar 

Tompkins, B. A. et al. IMPACT: Preclinical studies of cell therapy for human disease. Circ. Res. 122, 1006–1020 (2018).

Article  Google Scholar 

Ginty, P., Singh, P., Smith, D., Hourd, P. & Williams, D. Achieving reimbursement for regenerative medicine products in the USA. Regen. Med. 5, 463–469 (2010).

Article  Google Scholar 

Bubela, T. et al. Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. Regen. Med. 10, 897–911 (2015).

Article  Google Scholar 

Marks, L. V. Collaboration — a competitor’s tool: the story of Centocor, an entrepreneurial biotechnology company. Bus. History 51, 529–546 (2009).

Article  Google Scholar 

Cheever, M. A. & Higano, C. S. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 17, 3520–3526 (2011).

Article  Google Scholar 

Schmidt, C. Gintuit cell therapy approval signals shift at US regulator. Nat. Biotechnol. 30, 479–479 (2012).

Article  Google Scholar 

Schmidt, C. FDA approves first cell therapy for wrinkle-free visage. Nat. Biotechnol. 29, 674–675 (2011).

Article  Google Scholar 

Boss, W. K. et al. Autologous cultured fibroblasts as cellular therapy in plastic surgery. Clin. Plastic Surg. 27, 613–626 (2000).

Article  Google Scholar 

Morrison, C. Boom: 2018’s biotech IPOs. Nat. Rev. Drug Discov. 18, 3–6 (2019).

Article  Google Scholar 

Markert, M. L. et al. Successful formation of a chimeric human thymus allograft following transplantation of cultured postnatal human thymus. J. Immunol. 158, 998–1005 (1997).

Article  Google Scholar 

Markert, M. L. et al. Transplantation of thymus tissue in complete DiGeorge syndrome. N. Engl. J. Med. 341, 1180–1189 (1999).

Article  Google Scholar 

Markert, M. L. et al. Thymus transplantation in complete DiGeorge syndrome: immunologic and safety evaluations in 12 patients. Blood 102, 1121–1130 (2003).

Article  Google Scholar 

Markert, M. Parathyroid and thymus transplantation in DiGeorge syndrome subjects. US patent 0041854 A1 (2009).

Markert, M. L. Parathyroid and thymus transplantation in DiGeorge syndrome subjects. World patent application WO 107601 A3 (2006).

Markert, M. L. Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants. World patent application WO 165197 A1 (2019).

Markert, M. L. et al. Methods of determining the suitability of cultured thymus tissue for implantation into humans and associated methods of use. Canadian patent application 3150732 A1 (2021).

Allen-Hoffmann, B. L. et al. Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. J. Investig. Dermatol. 114, 444–455 (2000).

Article  Google Scholar 

Schurr, M. J. et al. Phase I/II clinical evaluation of stratagraft: a consistent, pathogen-free human skin substitute. J. Trauma. Acute Care Surg. 66, 866 (2009).

Article  Google Scholar 

US National Library of Medicine. StrataGraft™ skin tissue (human donor skin) in the surgical management of complex skin defects. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00618839 (2019).

Centanni, J. M. et al. StrataGraft Skin substitute is well-tolerated and is not acutely immunogenic in patients with traumatic wounds: results from a prospective, randomized, controlled dose escalation trial. Ann. Surg. 253, 672 (2011).

Article  Google Scholar 

US National Library of Medicine. StrataGraft® skin tissue as an alternative to autografting deep partial-thickness burns. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01437852 (2019).

US National Library of Medicine. StrataGraft® skin tissue as an alternative to autografting full-thickness complex skin defects. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03005054 (2016).

Gibson, A. L. F. et al. A phase 3, open-label, controlled, randomized, multicenter trial evaluating the efficacy and safety of StrataGraft® construct in patients with deep partial-thickness thermal burns. Burns 47, 1024–1037 (2021).

Article  Google Scholar 

US National Library of Medicine. StrataGraft skin tissue expanded access at specific study sites (StrataCAT). ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04123548 (2021).

US National Library of Medicine. Scarring in stratagraft-treated vs. autograft-treated burn wounds: a clinical and histological investigation. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04896346 (2022).

US National Library of Medicine. StrataGraft safety, tolerability and efficacy in pediatric subjects (StrataSTEPS). ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT05517902 (2023).

US National Library of Medicine. StrataGraft overlay of meshed autograft in full-thickness thermal Burns (StrataSOMA). ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04765202 (2023).

Russell, S. et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390, 849–860 (2017).

Article  Google Scholar 

Walsh, C. E. & Batt, K. M. Hemophilia clinical gene therapy: brief review. Transl. Res. 161, 307–312 (2013).

Article  Google Scholar 

US National Library of Medicine. Gene transfer clinical trial for spinal muscular atrophy type 1. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02122952 (2022).

Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713–1722 (2017).

Article  Google Scholar 

US National Library of Medicine. Study evaluating the safety and pharmacokinetics of JCAR017 in B-cell non-Hodgkin lymphoma (TRANSCEND-NHL-001). ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT02631044 (2023).

Anderson, D. E., Gridley, A. & Crawford, D. C. Next generation cartilage repair and the pre-arthroplasty patient. Oper. Tech. Sports Med. 30, 150956 (2022).

Article  Google Scholar